WEST PHARMACEUTICAL SERVICES INC
No SEC Form 4 filings for $WST in the last 30 days.
See all $WST insider activity →Wall Street analysts covering West Pharmaceutical (WST) have a consensus 'Strong Buy' rating, with 14 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' The bullish sentiment has slightly decreased from last month. The mean price target of $401.31 suggests a 14.7% upside, while the highest target at $459 implies a 31.2% potential gain.
West Pharmaceutical Services (WST) shares rose 38.1% since late March, outpacing its industry and the S&P 500. The company reported 13% organic revenue growth and 29% adjusted EPS growth in Q2, raised its 2026 outlook to 10-11% organic revenue growth, citing HVP demand, Annex 1 upgrades, GLP-1 exposure, and improving manufacturing productivity after a cyber incident.
West Pharmaceutical Services (WST) reported Q2 adjusted EPS of $2.37, up 28.8% and 13.9% above consensus, on revenue of $872.3 million, up 13.8% and above consensus. The company raised 2026 revenue guidance to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05, citing stronger HVP growth and wider margins.
Over the past 7 days, alphai's AI scored 1 news story mentioning WST (WEST PHARMACEUTICAL SERVICES INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent WST coverage spans financial news, market movers and earnings.
Potential price appreciation based on upgraded targets.
The article frames WST’s rally as fundamentals-led, anchored by raised guidance and accelerating HVP/GLP-1 demand plus productivity recovery.
Guidance increase and margin expansion strengthen the bull case for West’s High-Value Product (HVP) growth, while SmartDose and West Vantage execution remain key risks.
Improving HVP mix and margin expansion support the bull case, but the article flags a large forward valuation premium and execution risks.
The article frames WST as benefiting from sustained biologics and GLP-1-related packaging demand, with management reinstating a favorable long-term growth outlook.
alphai scores every news story that mentions WST with an AI model for sentiment and relevance, and aggregates insider trades from WEST PHARMACEUTICAL SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Wall Street analysts covering West Pharmaceutical (WST) have a consensus 'Strong Buy' rating, with 14 'Strong Buy' ratings, one 'Moderate Buy,' and two 'Holds.' The bullish sentiment has slightly decreased from last month. The mean price target of $401.31 suggests a 14.7% upside, while the highest target at $459 implies a 31.2% potential gain.
1 min readWest Pharmaceutical Services (WST) shares rose 38.1% since late March, outpacing its industry and the S&P 500. The company reported 13% organic revenue growth and 29% adjusted EPS growth in Q2, raised its 2026 outlook to 10-11% organic revenue growth, citing HVP demand, Annex 1 upgrades, GLP-1 exposure, and improving manufacturing productivity after a cyber incident.
4 min readWest Pharmaceutical Services (WST) reported Q2 adjusted EPS of $2.37, up 28.8% and 13.9% above consensus, on revenue of $872.3 million, up 13.8% and above consensus. The company raised 2026 revenue guidance to $3.345B-$3.380B and adjusted EPS to $8.85-$9.05, citing stronger HVP growth and wider margins.
5 min readWest Pharmaceutical Services (WST) reported Q2 organic sales up 12.7% and adjusted EPS up 28.8% to $2.37. HVP components were $424.1M, 49% of revenue, up 18.4% organically. Gross margin rose to 37.7% and operating margin to 22.6%. The article cites 2026 earnings expectations and a 37.1x forward multiple versus peers.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter says small-cap growth led markets, with the Russell 2000 Growth Index up 25.7% in Q2. The letter highlights West Pharmaceutical Services (NYSE:WST), noting a higher stock after another quarter of broad-based growth. It cites 15% organic revenue growth and a reinstated long-term outlook tied to biologics and GLP-1 demand.
4 min readWest Pharmaceutical Services reported higher Q2 2026 sales and earnings, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase, and kept its US$0.22 quarterly dividend. It also expanded a Daikyo Seiko distribution deal via new 10-year agreements, granting West exclusivity outside Japan and expanding Daikyo’s role in Japan.
5 min readWest Pharmaceutical Services (WST) said it signed a decade-long distribution agreement with Daikyo that extends beyond Japan, according to the company. The deal covers distribution of West’s products in additional markets over the 10-year term, which could affect future revenue and regional sales mix.
1 min readStocks including Hims & Hers Health (HIMS), Repligen (RGEN), West Pharmaceutical Services (WST), and 10x Genomics (TXG) fell after concerns about a rising number of uninsured patients. The article cites HCA Healthcare’s earnings report, saying a negative payer mix shift reduced its estimated pre-tax income by about $400 million in the quarter.
5 min readWest Pharmaceutical Services (NYSE:WST) reported Q2 revenue of $872 million, up 13% organically, and adjusted EPS of $2.37, up 29% year over year. The company raised its 2026 outlook to $3.345 billion-$3.38 billion revenue and adjusted EPS of $8.85-$9.05, citing strong high-value product components demand tied to biologics and GLP-1 elastomers, plus margin expansion and buybacks.
6 min readWest Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 revenue of $872.3 million, up 13.8% year on year and above market expectations by 3.5%, according to the company. Non-GAAP EPS was $2.37, 13.9% above consensus. Next-quarter revenue guidance midpoint was $827.5 million. Shares rose about 7.3% to $384.97 after results.
4 min read
